# Vasopressin Injection, USP

Safety Data Sheet

According To Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules And Regulations And According To The Hazardous Products Regulation (February 11, 2015).

Date of Issue: 05/25/2023 Version: 1.0

## SECTION 1: IDENTIFICATION

### 1.1. Product Identifier

**Product Form:** Mixture

**Product Name:** Vasopressin Injection, USP

**Synonyms:**

Vasopressin Injection, USP (SDV) – Preservative Free – PC 930101 – 1 mL fill per vial

Vasopressin Injection, USP (MDV) – Preserved – PC 930110- 10 mL fill per vial

1,2-Dithia-5,8,11,14,17-pentaazacycloeicosane-10-propionamide, 19-amino-13-benzyl-7-(carbamoylmethyl)-4-[2-[[1-[(carbamoylmethyl)carbamoyl]-4-guanidinobutyl]carbamoyl]-1-pyrrolidinylcarbonyl]-16-p-hydroxybenzyl-6,9,12,15,18-pentaoxo- injection

3-(Phenylalanine)-8-arginineoxytocin injection

[8-Arginine]vasopressin injection

8-L-Arginine-vasopressin injection

Arg8-vasopressin injection

Arginine-8-vasopressin injection

Arginine antidiuretic hormone injection

Arginine-vasopressin injection

Argipressin injection

AVP injection

Oxytocin, 3-(L-phenylalanine)-8-L-arginine- injection

Pitressin injection

Vasopressin, 8-L-arginine- injection

### 1.2. Intended Use of the Product

For intravenous administration to increase blood pressure in adults with vasodilatory shock (e.g post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.

### 1.3. Name, Address, and Telephone of the Responsible Party

**Manufacturer**

Fresenius Kabi USA

3159 Staley Road

Grand Island, NY 14072

(716) 773-0800

**Distributor**

Fresenius Kabi USA, LLC

Three Corporate Drive

Lake Zurich, IL 60047

General Phone Number: (847) 550-2300

Customer Service Phone Number: (888) 386-1300

Health Issues Information: (800) 551-7176

http://www.fresenius-kabi.com/us/

### 1.4. Emergency Telephone Number

**Emergency Number** : VelocityEHS
(800)255-3924 (North America)
+1 (813)248-0585 (International)

## SECTION 2: HAZARDS IDENTIFICATION

### 2.1. Classification of the Substance or Mixture

**GHS-US/CA Classification**

Not classified

### 2.2. Label Elements

**GHS-US/CA Labeling**

No labeling applicable according to 29 CFR 1910.1200 and the Hazardous Products Regulations (HPR) SOR/2015-17.

### 2.3. Other Hazards

No additional information available

### 2.4. Unknown Acute Toxicity (GHS-US/CA)

No additional information available

## SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

### 3.1. Substance

Not applicable

### 3.2. Mixture

| Name | Synonyms | Product Identifier | % * | GHS Ingredient Classification |
|---|---|---|---|---|
| Water | AQUA | (CAS-No.) 7732-18-5 | > 99 | Not classified |
| Chlorobutanol ** | Acetone chloroform / Anhydrous chlorobutanol / Chlorbutanol / 2-Propanol, 1,1,1-trichloro-2-methyl- / Chlorobutanol, anhydrous / Propan-2-ol, 1,1,1-trichloro-2-methyl- / 2-Propanol, 2-methyl-1,1,1-trichloro- / 1,1,1-Trichloro-2-methyl-2-propanol / 1,1,1-Trichloro-2-methylpropanol-2 / 1,1,1-Trichloro-2-methylpropan-2-ol / 2-Propanol, 1,1,1-trichloro-2-methyl-hydrate | (CAS-No.) 57-15-8 | 0.5 | Acute Tox. 4 (Oral), H302 |
| Sodium acetate trihydrate | Acetate, sodium, trihydrate / Acetic acid, sodium salt, trihydrate / Sodium acetate-3-hydrate / Acetic acid, sodium salt, hydrate (1:1:3) / Sodium acetate | (CAS-No.) 6131-90-4 | 0.14 | Combustible Dust |
| Hydrochloric acid | Hydrochloric acid, anhydrous / Muriatic acid / Hydrogen chloride | (CAS-No.) 7647-01-0 | < 0.1 | Met. Corr. 1, H290<br>Skin Corr. 1A, H314<br>Eye Dam. 1, H318<br>STOT SE 3, H335<br>Aquatic Acute 2, H401 |
| Sodium hydroxide | Sodium hydroxide (Na(OH)) / Caustic soda / Lye | (CAS-No.) 1310-73-2 | < 0.1 | Met. Corr. 1, H290<br>Acute Tox. 4 (Oral), H302<br>Skin Corr. 1A, H314<br>Eye Dam. 1, H318<br>STOT SE 1, H370<br>Aquatic Acute 3, H402 |
| Vasopressin | 1,2-Dithia-5,8,11,14,17-pentaazacycloeicosane-10-propionamide, 19-amino-13-benzyl-7-(carbamoylmethyl)-4-[2-[[1-[(carbamoylmethyl)carbamoyl]-4-guanidinobutyl]carbamoyl]-1-pyrrolidinylcarbonyl]-16-p-hydroxybenzyl-6,9,12,15,18-pentaoxo- / 3-(Phenylalanine)-8-arginineoxytocin / 8-L-Arginine-vasopressin / Arg8-vasopressin / Arginine antidiuretic hormone / Arginine-8-vasopressin / Arginine-vasopressin / AVP / Oxytocin, 3-(L-phenylalanine)-8-L-arginine- / Pitressin / Vasopressin, 8-L-arginine- / [8-Arginine]vasopressin / Argipressin | (CAS-No.) 113-79-1 | 0.004 | Acute Tox. 3 (Inhalation), H331<br>Repr. 1B, H360<br>STOT SE 1, H370 |

Full text of H-statements: see section 16

*Percentages are listed in weight by weight percentage (w/w%)

**Preservative. Not present in PC 930101

## SECTION 4: FIRST AID MEASURES

### 4.1. Description of First-aid Measures

**General:** Never give anything by mouth to an unconscious person. If you feel unwell, seek medical advice (show the label where possible).

**Inhalation:** When symptoms occur: go into open air and ventilate suspected area. Obtain medical attention if breathing difficulty persists.

**Skin Contact:** Remove contaminated clothing. Wash immediately with plenty of soap and water. Obtain medical attention if irritation develops or persists.

**Eye Contact:** Rinse cautiously with water for at least 5 minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Obtain medical attention if irritation develops or persists.

**Ingestion:** Rinse mouth. Do NOT induce vomiting. Obtain medical attention.

### 4.2. Most Important Symptoms and Effects Both Acute and Delayed

**General:** Common clinical side effects include: Cardiovascular - Cardiac arrest, circumoral pallor, arrhythmias, decreased cardiac output, angina, myocardial ischemia, peripheral vasoconstriction, and gangrene. Gastrointestinal - Abdominal cramps, nausea, vomiting, passage of gas. Nervous System - Tremor, vertigo, "pounding" in head. Respiratory - Bronchial constriction. Skin and Appendages - Sweating, urticaria, cutaneous gangrene. Overdosage - Water intoxication.

**Inhalation:** Prolonged exposure may cause irritation.

**Skin Contact:** Prolonged exposure may cause skin irritation.

**Eye Contact:** Prolonged exposure may cause slight irritation to eyes.

**Ingestion:** Ingestion of large quantities may have adverse effects.

**Chronic Symptoms:** None expected under normal conditions of use.

### 4.3. Indication of Any Immediate Medical Attention and Special Treatment Needed

If exposed or concerned, get medical advice and attention. If medical advice is needed, have product container or label at hand.

## SECTION 5: FIRE-FIGHTING MEASURES

### 5.1. Extinguishing Media

**Suitable Extinguishing Media:** Use extinguishing media suitable for surrounding type of fire.

**Unsuitable Extinguishing Media:** None known.

### 5.2. Special Hazards Arising From the Substance or Mixture

**Fire Hazard:** Not flammable.

**Explosion Hazard:** Product is not explosive.

**Reactivity:** Hazardous reactions will not occur under normal conditions.

### 5.3. Advice for Firefighters

**Precautionary Measures Fire:** Exercise caution when fighting any chemical fire.

**Firefighting Instructions:** Use water spray or fog for cooling exposed containers.

**Protection During Firefighting:** Do not enter fire area without proper protective equipment, including respiratory protection.

**Hazardous Combustion Products**: None known

### 5.4. Reference to Other Sections

Refer to Section 9 for flammability properties.

## SECTION 6: ACCIDENTAL RELEASE MEASURES

### 6.1. Personal Precautions, Protective Equipment and Emergency Procedures

**General Measures:** Avoid prolonged contact with eyes, skin and clothing. Avoid breathing (vapor, mist, spray).

#### 6.1.1. For Non-Emergency Personnel

**Protective Equipment:** Use appropriate personal protective equipment (PPE).

**Emergency Procedures:** Evacuate unnecessary personnel.

#### 6.1.2. For Emergency Personnel

**Protective Equipment:** Equip cleanup crew with proper protection.

**Emergency Procedures:** Upon arrival at the scene, a first responder is expected to recognize the presence of dangerous goods, protect oneself and the public, secure the area, and call for the assistance of trained personnel as soon as conditions permit. Ventilate area.

### 6.2. Environmental Precautions

Prevent entry to sewers and public waters.

### 6.3. Methods and Materials for Containment and Cleaning Up

**For Containment:** Contain any spills with dikes or absorbents to prevent migration and entry into sewers or streams.

**Methods for Cleaning Up:** Clean up spills immediately and dispose of waste safely. Transfer spilled material to a suitable container for disposal. Contact competent authorities after a spill.

### 6.4. Reference to Other Sections

See Section 8 for exposure controls and personal protection and Section 13 for disposal considerations.

## SECTION 7: HANDLING AND STORAGE

### 7.1. Precautions for Safe Handling

**Precautions for Safe Handling:** Wash hands and other exposed areas with mild soap and water before eating, drinking or smoking and when leaving work. Avoid prolonged contact with eyes, skin and clothing. Avoid breathing vapors, mist, spray.

**Hygiene Measures:** Handle in accordance with good industrial hygiene and safety procedures.

### 7.2. Conditions for Safe Storage, Including Any Incompatibilities

**Technical Measures:** Comply with applicable regulations.

**Storage Conditions:** Store at 2-8 °C / 36-46 °F. Do not freeze. Vials may be held up to 12 months upon removal from refrigeration to room temperature storage conditions (20-25 °C [68-77 °F], [see USP Controlled Room Temperature]), anytime within the labeled shelf life. Once removed from refrigeration, unopened vial should be marked to indicate the revised 12 month expiration date. If the manufacturer's original expiration date is shorter than the revised expiration date, then the shorter date must be used. Do not use Vasopressin injection beyond the manufacturer's expiration date stamped on the vial.

**Incompatible Materials:** Strong acids, strong bases, strong oxidizers.

**Storage Temperature:** 2-8 °C (36-46 °F). Do not freeze.

### 7.3. Specific End Use(s)

For intravenous administration to increase blood pressure in adults with vasodilatory shock (e.g post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.

## SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1. Control Parameters

For substances listed in section 3 that are not listed here, there are no established exposure limits from the manufacturer, supplier, importer, or the appropriate advisory agency including: ACGIH (TLV), AIHA (WEEL), NIOSH (REL), OSHA (PEL), or Canadian provincial governments.

| **Hydrochloric acid (7647-01-0)** | | |
|---|---|---|
| **USA ACGIH** | ACGIH OEL Ceiling | 2 ppm |
| **USA ACGIH** | ACGIH chemical category | Not Classifiable as a Human Carcinogen |
| **USA OSHA** | OSHA PEL Ceiling | 7 mg/m³ |
| **USA OSHA** | OSHA PEL C | 5 ppm |
| **USA NIOSH** | NIOSH REL Ceiling | 7 mg/m³ |
| **USA NIOSH** | NIOSH REL C | 5 ppm |
| **USA IDLH** | IDLH | 50 ppm |
| **Alberta** | OEL C | 3 mg/m³ |
| **Alberta** | OEL Ceiling | 2 ppm |
| **British Columbia** | OEL Ceiling | 2 ppm |
| **Manitoba** | OEL Ceiling | 2 ppm |
| **New Brunswick** | OEL C | 7.5 mg/m³ |
| **New Brunswick** | OEL Ceiling | 5 ppm |
| **Newfoundland & Labrador** | OEL Ceiling | 2 ppm |
| **Nova Scotia** | OEL Ceiling | 2 ppm |
| **Nunavut** | OEL Ceiling | 2 ppm |
| **Northwest Territories** | OEL Ceiling | 2 ppm |
| **Ontario** | OEL Ceiling | 2 ppm |
| **Prince Edward Island** | OEL Ceiling | 2 ppm |
| **Québec** | Plafond OEL Ceiling | 2 ppm |
| **Saskatchewan** | OEL Ceiling | 2 ppm |
| **Yukon** | OEL C | 7 mg/m³ |
| **Yukon** | OEL Ceiling | 5 ppm |

| **Sodium hydroxide (1310-73-2)** | | |
|---|---|---|
| **USA ACGIH** | ACGIH OEL Ceiling | 2 mg/m³ |
| **USA OSHA** | OSHA PEL TWA | 2 mg/m³ |
| **USA NIOSH** | NIOSH REL Ceiling | 2 mg/m³ |
| **USA IDLH** | IDLH | 10 mg/m³ |
| **Alberta** | OEL C | 2 mg/m³ |

| | | |
|---|---|---|
| **British Columbia** | OEL C | 2 mg/m³ |
| **Manitoba** | OEL C | 2 mg/m³ |
| **New Brunswick** | OEL C | 2 mg/m³ |
| **Newfoundland & Labrador** | OEL C | 2 mg/m³ |
| **Nova Scotia** | OEL C | 2 mg/m³ |
| **Nunavut** | OEL C | 2 mg/m³ |
| **Northwest Territories** | OEL C | 2 mg/m³ |
| **Ontario** | OEL C | 2 mg/m³ |
| **Prince Edward Island** | OEL C | 2 mg/m³ |
| **Québec** | Plafond OEL Ceiling | 2 mg/m³ |
| **Saskatchewan** | OEL C | 2 mg/m³ |
| **Yukon** | OEL C | 2 mg/m³ |

### 8.2. Exposure Controls

**Appropriate Engineering Controls:** Suitable eye/body wash equipment should be available in the vicinity of any potential exposure. Ensure adequate ventilation, especially in confined areas. Ensure all national/local regulations are observed.

**Personal Protective Equipment:** Gloves. Protective clothing. Protective goggles.

**Materials for Protective Clothing:** Chemically resistant materials and fabrics.

**Hand Protection:** Wear protective gloves.

**Eye and Face Protection:** Chemical safety goggles.

**Skin and Body Protection:** Wear suitable protective clothing.

**Respiratory Protection:** If exposure limits are exceeded or irritation is experienced, approved respiratory protection should be worn. In case of inadequate ventilation, oxygen deficient atmosphere, or where exposure levels are not known wear approved respiratory protection.

**Other Information:** When using, do not eat, drink or smoke.

## SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

### 9.1. Information on Basic Physical and Chemical Properties

| | | |
|---|---|---|
| **Physical State** | : | Liquid |
| **Appearance** | : | Colorless liquid |
| **Odor** | : | No data available |
| **Odor Threshold** | : | No data available |
| **pH** | : | No data available |
| **Evaporation Rate** | : | 3.8 |
| **Melting Point** | : | No data available |
| **Freezing Point** | : | No data available |
| **Boiling Point** | : | No data available |
| **Flash Point** | : | No data available |
| **Auto-ignition Temperature** | : | No data available |
| **Decomposition Temperature** | : | No data available |
| **Flammability (solid, gas)** | : | Not applicable |
| **Lower Flammable Limit** | : | No data available |
| **Upper Flammable Limit** | : | No data available |
| **Vapor Pressure** | : | No data available |
| **Relative Vapor Density at 20°C** | : | No data available |
| **Relative Density** | : | ≈ 1 |
| **Density** | : | 0.9967 – 0.9982 g/ml |
| **Specific Gravity** | : | No data available |
| **Solubility** | : | Water: Soluble |
| **Partition Coefficient: N-Octanol/Water** | : | No data available |

**Viscosity** : No data available

## SECTION 10: STABILITY AND REACTIVITY

**10.1. Reactivity:**

Hazardous reactions will not occur under normal conditions.

**10.2. Chemical Stability:**

Stable under recommended handling and storage conditions (see section 7).

**10.3. Possibility of Hazardous Reactions:**

Hazardous polymerization will not occur.

**10.4. Conditions to Avoid:**

Direct sunlight, extremely high or low temperatures, and incompatible materials.

**10.5. Incompatible Materials:**

Strong acids, strong bases, strong oxidizers.

**10.6. Hazardous Decomposition Products:**

Thermal decomposition may produce: Carbon oxides (CO, $CO_2$). Chlorine compounds. Nitrogen oxides. Sulfur oxides.

## SECTION 11: TOXICOLOGICAL INFORMATION

### 11.1. Information on Toxicological Effects - Product

**Likely routes of exposure:** Eye contact. Dermal. Ingestion.

**Acute Toxicity (Oral):** Not classified

**Acute Toxicity (Dermal):** Not classified

**Acute Toxicity (Inhalation):** Not classified

**LD50 and LC50 Data:** No additional information available

**Skin Corrosion/Irritation:** Not classified

**Eye Damage/Irritation:** Not classified

**Respiratory or Skin Sensitization:** Not classified

**Germ Cell Mutagenicity:** Not classified

**Carcinogenicity:** Not classified

**Specific Target Organ Toxicity (Repeated Exposure):** Not classified

**Reproductive Toxicity:** Not classified

**Specific Target Organ Toxicity (Single Exposure):** Not classified

**Aspiration Hazard:** Not classified

**Symptoms/Injuries After Inhalation:** Prolonged exposure may cause irritation.

**Symptoms/Injuries After Skin Contact:** Prolonged exposure may cause skin irritation.

**Symptoms/Injuries After Eye Contact:** Prolonged exposure may cause slight irritation to eyes.

**Symptoms/Injuries After Ingestion:** Ingestion of large quantities may have adverse effects.

**Chronic Symptoms:** None expected under normal conditions of use.

### 11.2. Information on Toxicological Effects - Ingredient(s)

**LD50 and LC50 Data:**

| **Hydrochloric acid (7647-01-0)** | |
|---|---|
| **LD50 Dermal Rabbit** | > 5010 mg/kg |

| **Sodium hydroxide (1310-73-2)** | |
|---|---|
| **LD50 Oral Rat** | 325 mg/kg |

| **Chlorobutanol (57-15-8)** | |
|---|---|
| **LD50 Oral Rat** | 510 mg/kg |

## SECTION 12: ECOLOGICAL INFORMATION

### 12.1. Toxicity

**Ecology - General:** Not classified.

| **Hydrochloric acid (7647-01-0)** | |
|---|---|
| **LC50 Fish** | 7.45 mg/l (Species: Oncorhynchus mykiss - Exposure time: 96h) |

| **Sodium hydroxide (1310-73-2)** | |
|---|---|
| **LC50 Fish** | 45.4 mg/l (Exposure time: 96 h - Species: Oncorhynchus mykiss [static]) |
| **EC50 Crustacea** | 40 mg/l |

### 12.2. Persistence and Degradability

| Vasopressin Injection, USP | |
|---|---|
| **Persistence and Degradability** | Not established. |

### 12.3. Bioaccumulative Potential

| Vasopressin Injection, USP | |
|---|---|
| **Bioaccumulative Potential** | Not established. |

| Chlorobutanol (57-15-8) | |
|---|---|
| **Partition coefficient n-octanol/water (Log POW)** | 2.16 (at 20 °C) |

### 12.4. Mobility in Soil

No additional information available

### 12.5. Other Adverse Effects

**Other Information:** Avoid release to the environment.

## SECTION 13: DISPOSAL CONSIDERATIONS

### 13.1. Waste treatment methods

**Waste Disposal Recommendations:** Dispose of contents/container in accordance with local, regional, national, territorial, provincial, and international regulations.

**Ecology - Waste Materials:** Avoid release to the environment.

## SECTION 14: TRANSPORT INFORMATION

The shipping description(s) stated herein were prepared in accordance with certain assumptions at the time the SDS was authored, and can vary based on a number of variables that may or may not have been known at the time the SDS was issued.

### 14.1. In Accordance with DOT

Not regulated for transport

### 14.2. In Accordance with IMDG

Not regulated for transport

### 14.3. In Accordance with IATA

Not regulated for transport

### 14.4. In Accordance with TDG

Not regulated for transport

## SECTION 15: REGULATORY INFORMATION

### 15.1. US Federal Regulations

| Water (7732-18-5) | |
|---|---|
| Listed on the United States TSCA (Toxic Substances Control Act) inventory - Status: Active | |

| Hydrochloric acid (7647-01-0) | |
|---|---|
| Listed on the United States TSCA (Toxic Substances Control Act) inventory - Status: Active<br>Listed on the United States SARA Section 302<br>Subject to reporting requirements of United States SARA Section 313 | |
| **CERCLA RQ** | 5000 lb |
| **SARA Section 302 Threshold Planning Quantity (TPQ)** | 500 lb (gas only) |
| **SARA Section 313 - Emission Reporting** | 1 % (acid aerosols including mists, vapors, gas, fog, and other airborne forms of any particle size) |

| Sodium hydroxide (1310-73-2) | |
|---|---|
| Listed on the United States TSCA (Toxic Substances Control Act) inventory - Status: Active | |
| **CERCLA RQ** | 1000 lb |

| Chlorobutanol (57-15-8) |
|---|
| Listed on the United States TSCA (Toxic Substances Control Act) inventory - Status: Active |

### 15.2. US State Regulations

| Hydrochloric acid (7647-01-0) |
|---|
| U.S. - New Jersey - Right to Know Hazardous Substance List |
| U.S. - Pennsylvania - RTK (Right to Know) List |
| U.S. - Massachusetts - Right To Know List |
| U.S. - Pennsylvania - RTK (Right to Know) - Environmental Hazard List |

| **Sodium hydroxide (1310-73-2)** |
|---|
| U.S. - New Jersey - Right to Know Hazardous Substance List |
| U.S. - Pennsylvania - RTK (Right to Know) List |
| U.S. - Massachusetts - Right To Know List |
| U.S. - Pennsylvania - RTK (Right to Know) - Environmental Hazard List |

### 15.3. Canadian Regulations

| **Water (7732-18-5)** |
|---|
| Listed on the Canadian DSL (Domestic Substances List) |

| **Hydrochloric acid (7647-01-0)** |
|---|
| Listed on the Canadian DSL (Domestic Substances List) |

| **Sodium hydroxide (1310-73-2)** |
|---|
| Listed on the Canadian DSL (Domestic Substances List) |

| **Chlorobutanol (57-15-8)** |
|---|
| Listed on the Canadian DSL (Domestic Substances List) |

## SECTION 16: OTHER INFORMATION, INCLUDING DATE OF PREPARATION OR LAST REVISION

**Date of Preparation or Latest Revision** : 05/25/2023

**Other Information** : This document has been prepared in accordance with the SDS requirements of the OSHA Hazard Communication Standard 29 CFR 1910.1200 and Canada's Hazardous Products Regulations (HPR) SOR/2015-17.

**GHS Full Text Phrases:**

| | |
|---|---|
| H290 | May be corrosive to metals |
| H302 | Harmful if swallowed |
| H314 | Causes severe skin burns and eye damage |
| H318 | Causes serious eye damage |
| H331 | Toxic if inhaled |
| H335 | May cause respiratory irritation |
| H360 | May damage fertility or the unborn child |
| H370 | Causes damage to organs |
| H401 | Toxic to aquatic life |
| H402 | Harmful to aquatic life |




**NFPA Health Hazard** : 0 - Materials that, under emergency conditions, would offer no hazard beyond that of ordinary combustible materials.

**NFPA Fire Hazard** : 0 - Materials that will not burn under typical fire conditions, including intrinsically noncombustible materials such as concrete, stone, and sand.

**NFPA Reactivity Hazard** : 0 - Material that in themselves are normally stable, even under fire conditions.

**HMIS III Rating**

**Health** : 0 Minimal Hazard

**Flammability** : 0 Minimal Hazard

**Physical** : 0 Minimal Hazard

*This information is based on our current knowledge and is intended to describe the product for the purposes of health, safety and environmental requirements only. It should not therefore be construed as guaranteeing any specific property of the product.*

NA GHS SDS 2015 (Can, US)